The number of completed clinical trials for medical devices in Q4 2021 saw a 70% decrease in the number of trials globally, when compared with the last four–quarters average, according to GlobalData’s medical devices database.

The global medical devices market was worth $479.97bn in 2020 and is expected to reach $532.37bn by 2023, according to GlobalData’s analysis.

Completed clinical trials by market: General Surgery has the most studies

Looking at the completed studies by the type of markets, General Surgery accounted for the largest proportion (16%) in Q4 2021, followed by Healthcare IT (16%) and Cardiovascular Devices (12%).

Of the global medical devices market value, the General Surgery market held a 10% share, worth $49bn in 2020 and is expected to reach $63.76bn by 2023.

North America leads completed trials activity

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Comparing the number of completed clinical trials for medical devices in different regions of the globe, North America held the leading position with a share of 49% in Q4 2021, followed by Europe with 31%, and Asia-Pacific with 15%.

At the country level, the US had the largest share (35%) of the completed global clinical trials during the quarter. In second place was France with a share of 7%, followed by Belgium with 5%.

Looking at the share of activity in terms of completed clinical trials sponsorship, company-sponsored trials accounted for a 62% share of the global medical devices market, while institute-sponsored trials held the remaining share.

The quarterly average for the last four quarters saw company-sponsored trials account for 49% of completed trials and institute-sponsored trials account for 51%.

The clinical trials data used for the analysis were extracted from the medical Clinical Trials Database of GlobalData’s Medical Intelligence Center. Medical device clinical trials database covers all clinical trials conducted on medical devices, combination devices, diagnostics, and diagnostic imaging agents covering 16 markets(as per medical device taxonomy). GlobalData tracks clinical trials from six key registries: NCT, UMIN, ACTRN, ChiCTR, EudraCT, and ISRCT. It also monitors universities, company websites, press releases, investor presentations and annual reports to track medical device clinical trials. Industry refers to commercial entities such as private and public companies and their subsidiaries. Non-Industry refers to non-profit making entities including hospitals, universities, government research institutions and non-government research institutions. The information is collected by following systematic research techniques and proprietary methodology. Only completed clinical trials are considered for this analysis